1995至2015年根治性膀胱切除术治疗尿路上皮癌的管理与结局趋势:纪念斯隆凯特琳经验
该研究回顾性分析了1995至2015年在纪念斯隆凯特琳接受根治性膀胱切除术的2740例非转移性尿路上皮癌患者,评估肿瘤学特征、结局及围手术期管理的变化趋势。结果显示5年疾病复发概率从1997年峰值42%降至2013年34%(p=0.045),5年癌症特异性死亡概率从36%降至24%(p=0.009),新辅助化疗使用率显著上升,pT0率升高,手术切缘阳性率下降,淋巴结检出数增加。结论认为结局改善可能与优化手术和围手术期管理有关。
要点
- 5年复发概率从1997年42%降至2013年34%(p=0.045)。
- 5年癌症特异性死亡概率从1997年36%降至2013年24%(p=0.009)。
- 2010至2015年57%的肌层浸润性膀胱癌患者接受新辅助化疗。
核心结论
- 21年间根治性膀胱切除术后复发概率和癌症特异性死亡概率显著下降。
- 新辅助化疗使用增加、pT0率升高、切缘阳性率下降和淋巴结检出数增加可能促成结局改善。
研究设计与样本
- 回顾性分析单中心机构数据库,纳入1995至2015年接受根治性膀胱切除术的2740例非转移性尿路上皮癌患者。
主要发现
- 5年疾病复发概率从1997年峰值42%降至2013年34%(p=0.045)。
- 5年癌症特异性死亡概率从1997年36%降至2013年24%(p=0.009)。
- 根治性膀胱切除术前非肌层浸润性疾病发生率未变,研究期间占30%至35%。
- 2010至2015年57%的肌层浸润性膀胱癌患者接受新辅助化疗。
- 1995至2015年手术切缘阳性率从10%降至2.5%,淋巴结检出数从7枚增至24枚。
临床怎么用
- 支持在肌层浸润性膀胱癌中合理应用新辅助化疗。
- 根治性膀胱切除术中应注重手术质量,包括阴性切缘和充分的淋巴结清扫。
局限性
- 回顾性单中心研究,结果可能受选择偏倚和时代混杂因素影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluated trends in oncologic characteristics and outcomes as well as perioperative management among patients undergoing radical cystectomy at Memorial Sloan Kettering from 1995 to 2015. MATERIALS AND METHODS: We retrospectively reviewed our institutional database to analyze changes in disease recurrence probability, cancer specific and all cause mortality, incidence of muscle invasive bladder cancer, use of perioperative chemotherapy, rate of positive soft tissue surgical margins and lymph node yield. RESULTS: In 2,740 patients with nonmetastatic urothelial carcinoma undergoing radical cystectomy from 1995 to 2015 the 5-year probability of disease recurrence decreased from a peak of 42% in 1997 to 34% in 2013 (p=0.045), while the 5-year probability of cancer specific mortality likewise declined from 36% in 1997 to 24% in 2013 (p=0.009). The incidence of nonmuscle invasive disease before radical cystectomy did not change, comprising 30% to 35% of patients across the study period. Use of neoadjuvant chemotherapy rose significantly as 57% of patients with muscle invasive bladder cancer from 2010 to 2015 received it. We observed a corresponding rise in complete pathological response (pT0) at radical cystectomy, as well as decreasing positive soft tissue surgical margins (10% to 2.5%) and rising lymph node yield (7 to 24) from 1995 to 2015. CONCLUSIONS: During a 21-year period outcomes after radical cystectomy at our institution improved significantly, as the probability of recurrence and cancer specific mortality decreased. Increasing use of neoadjuvant chemotherapy, rising pT0 rates, decreased positive soft tissue surgical margins and increasing lymph node yields likely contributed, suggesting that optimized surgical and perioperative care led to improved cancer outcomes in patients undergoing radical cystectomy.
引用
- Almassi N, Cha EK, Vertosick EA, et al. Trends in Management and Outcomes among Patients with Urothelial Carcinoma Undergoing Radical Cystectomy from 1995 to 2015: The Memorial Sloan Kettering Experience. J Urol. 2020. PMID: 32294398. doi:10.1097/JU.0000000000001071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。